An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata

Trial Profile

An Open-Label (Part A) and a Double-Blind, Randomized, Placebo Controlled (Part B) Study, With an Open-Label Extension, of INCB018424 Phosphate Cream Applied Topically to Subjects With Alopecia Areata

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 May 2017

At a glance

  • Drugs Ruxolitinib (Primary)
  • Indications Alopecia areata
  • Focus Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 04 May 2017 According to an Incyte Corporation media release, after 24 weeks of treatment, the company has determined that data from this trial do not justify progression of the program into pivotal studies.
    • 01 Nov 2016 According to Incyte Corporation media release, data from this trial have been accepted for presentation at the National Alopecia Areata Foundation's Alopecia Areata Research Summit on November 14, 2016.
    • 10 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top